• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

FDPS Gene Record

  • Summary
  • Interactions
  • Claims
  • FDPS 2224 Druggable Genome

    Alternate Names:

    2224
    FARNESYL DIPHOSPHATE SYNTHASE
    FDPS
    FPPS
    FPS
    POROK9
    134629
    3631
    ENSG00000160752
    OTTHUMG00000013909
    P14324
    FPP synthase
    Geranyltranstransferase
    Dimethylallyltranstransferase
    (2E,6E)-farnesyl diphosphate synthase
    Farnesyl pyrophosphate synthase
    KIAA1293
    PA28075
    FPPS_HUMAN
    T86528

    Gene Info:

    Target Main Class Enzymes
    Target Subclass 2.5.1.-
    Target Class Enzymes
    Target Subclass EC:2.5.1.10
    Target Subclass EC:2.5.1.-
    Gene Biotype PROTEIN_CODING
    (6 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME
    ENZYME

    Publications:

    Coxon et al., 2005, Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo., Bone
    Dunford et al., 2001, Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates., J. Pharmacol. Exp. Ther.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Ortiz-Gómez et al., 2006, Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate., Eukaryotic Cell
    Russell et al., 2007, Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy., Ann. N. Y. Acad. Sci.
    Bergstrom et al., 2000, Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase., Arch. Biochem. Biophys.
    Gritzalis D et al., 2015, Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase., Bioorg Med Chem Lett
    Yokoyama T et al., 2015, Protonation State and Hydration of Bisphosphonate Bound to Farnesyl Pyrophosphate Synthase., J Med Chem
    Marini F et al., 2011, Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw., Front Biosci (Elite Ed)
    Chapurlat et al., 2006, Drug insight: Bisphosphonates for postmenopausal osteoporosis., Nat Clin Pract Endocrinol Metab
    Rondeau et al., 2006, Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs., ChemMedChem
    Scrima M et al., 2014, Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase., J Med Chem
    Pérez-Castrillón JL et al., 2014, Polymorphisms of the farnesyl diphosphate synthase gene modulate bone changes in response to atorvastatin., Rheumatol Int
    Olmos JM et al., 2012, Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates., Pharmacogenomics J
    Riebeling et al., 2002, The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro., Br. J. Cancer
    Zhang et al., 2004, Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy., Ann. Clin. Lab. Sci.
    Notarnicola et al., 2004, Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis., Oncology
  • IBANDRONIC ACID   FDPS

    Interaction Score: 18.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name ibandronate, R484,Boniva, Bonviva, Bondronat
    Novel drug target Established target

    PMIDs:
    16932286 16892359 11752352 11160603


    Sources:
    TdgClinicalTrial TEND TTD

  • RISEDRONIC ACID   FDPS

    Interaction Score: 15.46

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name risedronate sodium, NE-58095,Actonel, Benet, Atelvia
    Novel drug target Established target
    Trial Name -

    PMIDs:
    16006204 11160603 11752352 16835450 18056045 10620343 25630225 26314394


    Sources:
    DTC TdgClinicalTrial TEND TTD

  • RIBOPRINE   FDPS

    Interaction Score: 10.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25184810


    Sources:
    DTC

  • PAMIDRONIC ACID   FDPS

    Interaction Score: 9.27

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    12177810 11160603 15487700 11752352 15713990 10620343


    Sources:
    TdgClinicalTrial TEND TTD

  • IBANDRONATE SODIUM   FDPS

    Interaction Score: 5.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Farnesyl diphosphate synthase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PAMIDRONATE DISODIUM   FDPS

    Interaction Score: 5.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Farnesyl diphosphate synthase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • RISEDRONATE SODIUM   FDPS

    Interaction Score: 5.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Farnesyl diphosphate synthase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ALENDRONATE SODIUM   FDPS

    Interaction Score: 5.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Farnesyl diphosphate synthase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ZOLEDRONIC ACID   FDPS

    Interaction Score: 5.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Farnesyl diphosphate synthase inhibitor
    Direct Interaction yes
    Trial Name Zoledronic

    PMIDs:
    21196316


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • ALENDRONIC ACID   FDPS

    Interaction Score: 1.93

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TEND TTD

  • TIPIFARNIB   FDPS

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ATORVASTATIN   FDPS

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24311107 21151198


    Sources:
    PharmGKB

  • Ensembl: ENSG00000160752

    • Version: 101_38

    Alternate Names:
    FDPS Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: P14324

    • Version: January-2014

    Alternate Names:
    FDPS Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:2.5.1.10
    Target Subclass EC:2.5.1.-

    Publications:

  • TEND: P14324

    • Version: 01-August-2011

    Alternate Names:
    FDPS Gene Symbol
    P14324 Uniprot Accession
    ENSG00000160752 Ensembl Gene Id

    Gene Info:
    Target Main Class Enzymes
    Target Subclass 2.5.1.-

    Publications:

  • PharmGKB: FDPS

    • Version: 18-August-2020

    Alternate Names:
    PA28075 PharmGKB ID

    Gene Info:

    Publications:
    Marini F et al., 2011, Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw., Front Biosci (Elite Ed)
    Marini F et al., 2008, Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis., Curr Med Res Opin
    Pérez-Castrillón JL et al., 2014, Polymorphisms of the farnesyl diphosphate synthase gene modulate bone changes in response to atorvastatin., Rheumatol Int

  • DTC: FDPS

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Gritzalis D et al., 2015, Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase., Bioorg Med Chem Lett
    Yokoyama T et al., 2015, Protonation State and Hydration of Bisphosphonate Bound to Farnesyl Pyrophosphate Synthase., J Med Chem
    Scrima M et al., 2014, Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase., J Med Chem

  • HingoraniCasas: ENSG00000160752

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000160752 Gene Symbol
    FDPS Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: FPS

    • Version: chembl_23

    Alternate Names:
    KIAA1293 GENE_SYMBOL
    FDPS GENE_SYMBOL
    Farnesyl pyrophosphate synthase UNIPROT

    Gene Info:

    Publications:

  • Tempus: FDPS

    • Version: 11-November-2018

    Alternate Names:
    FDPS Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • TTD: Geranyltranstransferase

    • Version: 2020.06.01

    Alternate Names:
    FDPS TTD Gene Abbreviation
    T86528 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: FDPS

    • Version: 01-February-2022

    Alternate Names:
    Farnesyl pyrophosphate synthase Gene Name
    P14324 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21